Evolution Of Disease Activity And Biomarkers On And Off Rapamycin In 28 Patients With Autoimmune Lymphoproliferative Syndrome
This is a Letter to the Editor describing 28 cases of autoimmune lymphoproliferative syndrome (ALPS) treated with rapamycin therapy, addressing first- versus second-line therapy, comprehensive biomarker responses, and the consequences of stopping rapamycin.
Very useful description of a patient cohort treated with rapamycin. Also giving advice on levels of rapamycin that are usually active in this particular cohort.
